Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

July 31, 2026

Conditions

Advanced Breast CancerHormone-receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast

Interventions

DRUG

SHR-A1921

Anti-TROP-2 ADC

DRUG

Adebrelimab

PD-L1 inhibitor

Trial Locations (1)

Fudan Cancer Hospital, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER